Holen Sie sich die Stockscreener-App
17.89
3.71%
0.64
Schlusskurs vom Vortag:
$17.25
Offen:
$17.48
24-Stunden-Volumen:
1.65M
Relative Volume:
0.71
Marktkapitalisierung:
$1.80B
Einnahmen:
$352.57M
Nettoeinkommen (Verlust:
$-143.01M
KGV:
-9.884
EPS:
-1.81
Netto-Cashflow:
$-153.40M
1W Leistung:
+2.76%
1M Leistung:
+7.64%
6M Leistung:
-25.61%
1J Leistung:
-24.80%
1-Tages-Spanne:
$17.18
$17.96
1-Wochen-Bereich:
$16.65
$19.15
52-Wochen-Spanne:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
Firmenname
Beam Therapeutics Inc
Sektor
Branche
Telefon
857-327-8775
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Vergleichen Sie BEAM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
17.89 | 1.75B | 352.57M | -143.01M | -153.40M | -1.81 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-28 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-10 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-08 | Herabstufung | Jefferies | Buy → Hold |
| 2023-10-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Eingeleitet | Citigroup | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-01-05 | Eingeleitet | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-24 | Fortgesetzt | Stifel | Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Redburn | Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-08-05 | Eingeleitet | William Blair | Outperform |
| 2020-03-02 | Eingeleitet | Barclays | Overweight |
| 2020-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2020-03-02 | Eingeleitet | Jefferies | Buy |
| 2020-03-02 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten
Mercer Global Advisors Inc. ADV Sells 4,568 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Tower Research Capital LLC TRC Sells 5,172 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Beam Therapeutics to Highlight New Data from BEAM-101 Program in - GuruFocus
Beam Therapeutics to Present Updated Data on BEAM-101 in Sickle Cell Disease at EHA2025 Conference - Nasdaq
Beam Therapeutics to Highlight New Data from BEAM-101 - GlobeNewswire
New Clinical Data Reveals: BEAM-101 Treatment Progress in 17 Sickle Cell PatientsKey Findings Coming - Stock Titan
News: The Latest Clinical Trial Updates from CRISPR Medicine News - CRISPR Medicine News
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Purchased by Northern Trust Corp - Defense World
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Purchased by Stifel Financial Corp - Defense World
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference - GlobeNewswire
Beam Therapeutics (BEAM) Gains FDA RMAT Designation for BEAM-302 - GuruFocus
Beam : FDA Grants RMAT Designation To BEAM-302 For Alpha-1 Antitrypsin Deficiency Treatment - Nasdaq
FDA grants RMAT status to Beam’s AATD gene therapy - Investing.com
Beam Therapeutics Announces U.S. FDA Regenerative Medicine - GlobeNewswire
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - Stock Titan
HC Wainwright Issues Positive Forecast for BEAM Earnings - Defense World
FY2025 EPS Estimates for BEAM Cut by Cantor Fitzgerald - Defense World
(BEAM) Investment Report - news.stocktradersdaily.com
Wells Fargo & Company Cuts Beam Therapeutics (NASDAQ:BEAM) Price Target to $70.00 - Defense World
Guggenheim Cuts Beam Therapeutics (NASDAQ:BEAM) Price Target to $55.00 - Defense World
Q2 EPS Forecast for Beam Therapeutics Reduced by Analyst - Defense World
Is Beam Therapeutics (NASDAQ:BEAM) In A Good Position To Invest In Growth? - Yahoo Finance
Guggenheim Lowers Price Target for Beam Therapeutics (BEAM) | BE - GuruFocus
Guggenheim Lowers Price Target for Beam Therapeutics (BEAM) | BEAM Stock News - GuruFocus
BEAM Stock: Wells Fargo Analyst Lowers Price Target to $70 | BEAM Stock News - GuruFocus
BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates - The Globe and Mail
Barclays Adjusts Price Target for Beam Therapeutics (BEAM) | BEA - GuruFocus
Barclays Adjusts Price Target for Beam Therapeutics (BEAM) | BEAM Stock News - GuruFocus
10 Analysts Assess Beam Therapeutics: What You Need To Know - Benzinga
Guggenheim Adjusts Price Target for Beam Therapeutics (BEAM) Amid Ongoing Developments | BEAM Stock News - GuruFocus
Beam Therapeutics price target lowered to $55 from $78 at Guggenheim - TipRanks
Beam Therapeutics (BEAM) Target Price Cut by Wells Fargo Analyst | BEAM Stock News - GuruFocus
Barclays Adjusts Price Target for Beam Therapeutics (BEAM) to $2 - GuruFocus
Barclays Adjusts Price Target for Beam Therapeutics (BEAM) to $25 | BEAM Stock News - GuruFocus
Beam Therapeutics Reports Strong Q1 2025 Progress - TipRanks
Decoding Beam Therapeutics Inc (BEAM): A Strategic SWOT Insight - GuruFocus
Why Beam Therapeutics (BEAM) Stock Plummeted Today - GuruFocus
Why Beam Therapeutics Stock Tanked on Tuesday - AOL.com
Why Beam Therapeutics Stock Tanked On Tuesday - Barchart.com
Beam Therapeutics Inc Reports Q1 2025 Earnings: EPS of -$1.24 Mi - GuruFocus
Beam Therapeutics Shares Fall After Q1 Net Loss Widens - marketscreener.com
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Beam (BEAM) Reports Lower-than-Expected Q1 Revenue, Advances Cli - GuruFocus
Beam Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings Flash (BEAM) Beam Therapeutics Posts Q1 License and Collaboration Revenue $7.5M - marketscreener.com
Beam Therapeutics Inc. SEC 10-Q Report - TradingView
Earnings Flash (BEAM) Beam Therapeutics Posts Q1 Loss $1.24, vs. FactSet Est of -$1.18 - marketscreener.com
Beam (BEAM) Reports Lower-than-Expected Q1 Revenue, Advances Clinical Programs | BEAM Stock News - GuruFocus
Beam Therapeutics Inc. Q1 Loss Increases, Misses Estimates - Nasdaq
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Finanzdaten der Beam Therapeutics Inc-Aktie (BEAM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):